US Exchange Filings

Phio Pharmaceuticals Receives Nasdaq Notice for Bid-Price Noncompliance

Phio Pharmaceuticals has 180 days to bring its closing share price back to at least $1 after 30 consecutive business days below Nasdaq’s threshold. Trading and its listing are unaffected for now, but investors will be watching the company’s next steps.

Phio Pharmaceuticals has received notice that its share price has fallen below Nasdaq’s $1 minimum bid-price requirement for 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing or trading, and Phio has until May 17, 2027, to regain compliance.

  • Phio can meet the requirement if its closing bid price is at least $1 per share for 10 consecutive business days before the deadline.
  • The company says it will monitor its share price and evaluate options for regaining compliance. It did not specify what actions it may take.
  • The notice starts a 180-day compliance period; it does not mean Phio’s stock is being delisted now.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.